Vandortuzumab vedotin

Last updated
Vandortuzumab vedotin
Vedotin ADCs.svg
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target STEAP1
Clinical data
Other namesRG7450
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6608H10168N1756O2076S44
Molar mass 148838.89 g·mol−1

Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer. [1] [2]

This drug was developed by Genentech/Roche. Development was discontinued in 2017. [3]

Related Research Articles

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

<span class="mw-page-title-main">Bradanicline</span> Chemical compound

Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.

<span class="mw-page-title-main">Monomethyl auristatin E</span> Chemical compound

Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.

Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer.

Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.

Polatuzumab vedotin, sold under the brand name Polivy, is a CD79b-directed antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). It was developed by the Genentech subsidiary of Roche.

Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer and other gastrointestinal cancers. It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).

Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.

Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association .
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
  3. "Vandortuzumab vedotin". AdisInsight. Springer Nature Switzerland AG.